|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Morocco
Espicom Business Intelligence Ltd, Oct 2011, Pages: 78
THE PHARMACEUTICAL MARKET: MOROCCO - REVIEW
The Moroccan economy is expected to grow by a moderate CAGR in US dollar terms between 2011 and 2016. The national health insurance scheme (AMO) is expected to provide substantial additional funding for the health sector. Initially aimed at salaried workers, the scheme has been expanded to cover the self-employed. The CNSS, which operates the scheme in the private sector, announced that it would be extending cover to ambulatory care, in addition to hospital treatment. A health insurance scheme for those on very low incomes is still in the early stages of implementation and is expected to be rolled out on a national basis in 2011.
Although the Moroccan pharmaceutical market is small in global terms, per capita spending on pharmaceutical products is comparatively high for an African country, where average per capita income is just above US$3,000. The pharmaceutical market, which was stagnating prior to the launch of the universal health insurance scheme in 2006, is expected to grow by a moderate CAGR between 2011 and 2016. Around 2,600 drugs are eligible for reimbursement under the national health insurance scheme. Reimbursement is made on the basis of the retail price of generic products, where these exist. The government cut drug prices and encouraged generic consumption in 2010, following a parliamentary report published in 2009.
Over 50% of the pharmaceutical companies operating in the country are owned by foreign interests, and these companies are responsible for more than half of industry turnover. Multinationals with a strong presence in the Moroccan pharmaceutical market include Sanofi, GlaxoSmithKline and Pfizer. Hikma is also expected to increase its market penetration, following its acquisition of 63.9% of Promopharm, announced in October 2011. Independent local manufacturers primarily manufacture under licence or produce generics. Leading indigenous producers include Cooper Pharma, Laprophan and Sothéma. In September 2010, Cooper Pharma signed a technology transfer agreement with the Taiwanese Orient Europharma (OE) for the production of two medicaments developed for the treatment of sleeping disorders and diabetes.
ENHANCED STRATEGIC INTELLIGENCE
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
Also available
The Pharmaceutical Market: Egypt
The Pharmaceutical Market: Turkey
The Pharmaceutical Market: Saudi Arabia
The Pharmaceutical Market: Jordan
The Outlook for Pharmaceuticals in the Middle East and North Africa
Customers who bought this item also bought
The Outlook for Pharmaceuticals in the Middle East and North Africa
The Pharmaceutical Market: Pakistan
The Pharmaceutical Market: Canada
The Pharmaceutical Market: Croatia
The Pharmaceutical Market: Latvia
The Pharmaceutical Market: Germany
The Pharmaceutical Market: Malaysia
The Pharmaceutical Market: Switzerland
The Pharmaceutical Market: Australia
The Pharmaceutical Market: Ireland
|
|
|
|
